Dr. Richard Jefferson of Cambia shares his experience about non-exclusive patent licensing and how it is crucial for future explorations and innovations in the field of biotechnology.

The big multinational biotech companies can grant or deny the legal use of biological information due to which independent research organizations usually suffer. Patent restriction debate has escalated for past few years. Independent organizations like Bios has successfully dented the monopoly of big firms. Dr. Richard Jefferson talks to Newsclick about the issue.